Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-d…
$14.41+8.59%
报价 2026-11-06
市值
$5.04B
EV
$5.74B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -35.9%
$2.29$22.47
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ERASErasca, Inc. | $5.04B | +8.6% | +837.5% | 0% | – | – | – | |
| IOVAIovance Biotherapeutics, Inc. | $3.64B | +3.9% | +41.2% | 48.4% | – | – | – | |
| MBXMBX Biosciences, Inc. Common Stock | $2.47B | +6.0% | – | 0% | – | – | – | |
| MLTXMoonLake Immunotherapeutics | $981.3M | +6.8% | – | 0% | – | – | – | |
| CRVSCorvus Pharmaceuticals, Inc. | $886.6M | +8.3% | -133.3% | 0% | – | – | – | |
| MGTXMeiraGTx Holdings plc | $864.4M | +5.8% | +105.7% | 91.6% | – | – | – | |
| AVBPArriVent BioPharma, Inc. Common Stock | $672.6M | +11.5% | -98.2% | 0% | – | – | – | |
| VALNValneva SE | $524.2M | -2.3% | – | 29.5% | – | – | – | |
| CTMXCytomX Therapeutics, Inc. | $477.2M | +2.3% | -60.2% | 99.3% | – | – | – | |
| 同行中位数 | – | – | -60.2% | 14.7% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。